Monitor for complete Phase 1b data for ATTO-1310 in Q4 2026, which will determine the magnitude of the Phase 2 program. The strong cash runway removes near-term dilution risk, making pipeline execution the primary catalyst. Insider buying of $20.2M in the past 30 days aligns with positive sentiment.
Price Chart
Executive Summary
Attovia Therapeutics reported Q2 2026 results with a net loss of $20.7M (vs $14.4M in Q2 2025) and minimal collaboration revenue of $0.5M. The key positive catalyst is the preliminary clinical proof of concept for lead candidate ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, combined with an upsized IPO that raised $332.4M gross ($305.4M net), extending cash runway into 2030. The stock will move on pipeline validation and strong balance sheet, not the quarterly financials.
Key Financial Metrics
Key Facts
- Upsized IPO completed in August 2026 with gross proceeds of $332.4M and net proceeds of ~$305.4M
- Cash, cash equivalents and marketable securities were $115.1M as of June 30, 2026; post-IPO cash expected to fund operations into 2030
- ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch AD with rapid, deep itch relief and lesion control
- Complete Phase 1b data for ATTO-1310 expected in Q4 2026; Phase 2 studies in CPUO and high-itch AD planned for 1H 2027
- IND clearances received for ATTO-1310 in cholestatic pruritus (China) and for ATTO-2306 and ATTO-1091 IND-enabling activities ongoing with Phase 1 starts in 1H 2027
- Net loss widened to $20.7M in Q2 2026 from $14.4M in Q2 2025, driven by increased R&D spending on clinical and manufacturing activities
Financial Impact
IPO raised $332.4M gross, net ~$305.4M, extending cash runway into 2030; Q2 net loss $20.7M with minimal revenue of $0.5M
Risk Factors
- Clinical trial failure or disappointing Phase 1b data in Q4 2026 could reverse sentiment
- Competition from other IL-31 and IL-13 targeting therapies in pruritus and atopic dermatitis
- Need for additional financing beyond 2030 if pipeline milestones are delayed or require larger trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3355492 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 3/A | $16.21 | awaiting T+20 | — | $15.00 (−7.46%) |
Oct 8, 2026 19d ago | 3/A | $16.21 | awaiting T+20 | — | $15.00 (−7.46%) |
Sep 28, 2026 29d ago | Press Release | $18.16 $15.00 | ▼ −17.40% | ▼ −18.12% | $15.00 (−17.40%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $15.00 (−38.02%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $15.00 (−29.91%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $15.00 (−24.47%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $15.00 (−24.47%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $15.00 (−19.57%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $15.00 (−24.40%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $15.00 (−25.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers